Literature DB >> 11641780

Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene.

R Meuwissen1, S C Linn, M van der Valk, W J Mooi, A Berns.   

Abstract

The onset of human lung cancer occurs through sequential mutations in oncogenes and tumor suppressor genes. Mutations in K-Ras play a prominent role in human non-small cell lung cancer. We have developed a mouse lung tumor model in which K-Ras can be sporadically activated through Cre-lox mediated somatic recombination. Adenoviral mediated delivery of Cre recombinase in lung epithelial cells gave rise to rapid onset of tumorigenesis, yielding pulmonary adenocarcinomas with 100% incidence after a short latency. The lung tumor lesions shared many features with human non-small cell lung cancer. Our data show that sporadic expression of the K-Ras oncogene is sufficient to elicit lung tumorigenesis. Therefore this model has many advantages over conventional transgenic models used thus far.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11641780     DOI: 10.1038/sj.onc.1204837

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

1.  Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene.

Authors:  Elena V Antontseva; Marina Yu Matveeva; Natalia P Bondar; Elena V Kashina; Elena Yu Leberfarb; Leonid O Bryzgalov; Polina A Gervas; Anastasia A Ponomareva; Nadezhda V Cherdyntseva; Yury L Orlov; Tatiana I Merkulova
Journal:  J Biosci       Date:  2015-12       Impact factor: 1.826

2.  Stem cells are dispensable for lung homeostasis but restore airways after injury.

Authors:  Adam Giangreco; Esther N Arwert; Ian R Rosewell; Joshua Snyder; Fiona M Watt; Barry R Stripp
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

Review 3.  Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models.

Authors:  Harm HogenEsch; Alexander Yu Nikitin
Journal:  J Control Release       Date:  2012-03-14       Impact factor: 9.776

4.  Cell of origin of lung cancer.

Authors:  Kate D Sutherland; Anton Berns
Journal:  Mol Oncol       Date:  2010-06-08       Impact factor: 6.603

5.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.

Authors:  Kenneth E Hung; Marco A Maricevich; Larissa Georgeon Richard; Wei Y Chen; Michael P Richardson; Alexandra Kunin; Roderick T Bronson; Umar Mahmood; Raju Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

6.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

7.  Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.

Authors:  William W Lockwood; Raj Chari; Bradley P Coe; Kelsie L Thu; Cathie Garnis; Chad A Malloff; Jennifer Campbell; Ariane C Williams; Dorothy Hwang; Chang-Qi Zhu; Timon P H Buys; John Yee; John C English; Calum Macaulay; Ming-Sound Tsao; Adi F Gazdar; John D Minna; Stephen Lam; Wan L Lam
Journal:  PLoS Med       Date:  2010-07-27       Impact factor: 11.069

Review 8.  Mouse models for lung cancer.

Authors:  Min-chul Kwon; Anton Berns
Journal:  Mol Oncol       Date:  2013-02-19       Impact factor: 6.603

9.  Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.

Authors:  Yian Wang; Weidong Wen; Yijun Yi; Zhongqiu Zhang; Ronald A Lubet; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

Review 10.  Rebuilding cancer metastasis in the mouse.

Authors:  Meera Saxena; Gerhard Christofori
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.